Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes

• Published in: Clinical diabetes Vol. 38; no. 1; pp. 40 - 46
• Main Authors: Niccum, Blake A, Stine, Jonathan G, Wynter, Javelle A, Kelly, Virginia, Caldwell, Stephen H, Shah, Neeral L
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01-01-2020
• Subjects: Antiviral drugs; Diabetes; Disease management; Hepatitis; Hepatitis C; Risk factors
• ISSN: 0891-8929; 1945-4953
• DOI: 10.2337/cd18-0112

Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.